

**HB0633/593725/1**

BY: Health Committee

AMENDMENTS TO HOUSE BILL 633

(First Reading File Bill)

AMENDMENT NO. 1

On page 1, in the sponsor line, strike “**and Terrasa**” and substitute “**Terrasa, Bagnall, Cullison, Guzzone, Hutchinson, S. Johnson, Kipke, Lopez, Martinez, Reilly, Rosenberg, Ross, Taveras, White Holland, and Woorman**”; in line 3, strike “**and Prohibited Cost Sharing**”; in line 5, strike “individuals with” and substitute “coverage for opportunistic”; in the same line, strike “coverage”; and strike beginning with “prohibiting” in line 6 down through “coverage;” in line 8.

AMENDMENT NO. 2

On page 2, in lines 4 and 5, strike “**AN INDIVIDUAL WITH**” and substitute “**COVERAGE FOR OPPORTUNISTIC**”; in line 5, strike “**COVERAGE**”; strike in their entirety lines 6 through 14, inclusive; in line 15, after “That” insert “Section 1 of”; after line 17, insert:

“SECTION 3. AND BE IT FURTHER ENACTED, That, on or before December 1, 2026, the Maryland Health Care Commission shall:

(1) conduct a mandated benefits study of coverage of salpingectomy that is not opportunistic for individuals who are not at high risk of ovarian cancer, including consideration of existing practice guidance issued by the American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncology as well as the differences in efficacy of nonopportunistic salpingectomy versus the efficacy of opportunistic salpingectomy for individuals who are not at high risk; and

(2) report the findings of the study to the Senate Finance Committee and the House Health Committee, in accordance with § 2-1257 of the State Government Article.”;

in line 18, strike “3.” and substitute “4.”; in the same line, after “That” insert “Sections 1 and 2”; and after line 19, insert:

“SECTION 5. AND BE IT FURTHER ENACTED, That, except as provided in Section 4 of this Act, this Act shall take effect July 1, 2026.”.